Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger

Soleno Therapeutics Inc. (NASDAQ:SLNO) is 1 of the 10 Stocks With Unexpected Gains.

Soleno Therapeutics soared by 32.31 percent connected Monday to adjacent astatine $52.25 apiece, arsenic investors gobbled up shares pursuing quality that it is acceptable to beryllium acquired by Neurocrine Biosciences Inc. astatine a 34-percent upside.

In a statement, Neurocrine said that it entered into a definitive statement with Soleno Therapeutics Inc. (NASDAQ:SLNO) for the acquisition of each its issued and outstanding shares astatine a terms of $53 apiece, for a full of $2.9 billion.

Prior to the announcement, Soleno Therapeutics Inc. (NASDAQ:SLNO) past traded astatine $39.49.

The merger is acceptable to grow Neurocrine’s portfolio of innovative medicines, with the summation of VYKAT XR, and fortify its enactment presumption successful endocrinology and uncommon disease.

Since securing the support of the Food and Drug Administration past year, VYKAT XR has already generated $190 cardinal successful 2025 revenues for Soleno Therapeutics Inc. (NASDAQ:SLNO), of which $92 cardinal was registered successful the 4th fourth alone.

“Neurocrine is the close strategical spouse to grow the scope of VYKAT XR successful the Prader-Willi syndrome community, fixed their acquisition successful endocrinology and uncommon illness and their proven quality to execute palmy commercialized launches. We are excited to accelerate VYKAT XR’s interaction for PWS patients pursuing completion of the transaction by leveraging Neurocrine’s beardown commercialized capabilities,” said Soleno Therapeutics Inc. (NASDAQ:SLNO) Chairman and Chief Executive Officer Anish Bhatnagar.

While we admit the imaginable of SLNO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.